Skip to main content

Tandem Diabetes Care, Inc. (TNDM)

New York Stock Exchange Healthcare Medical - DevicesView data quality →
33.6Poor

ValueMarkers Composite Index

Top 1%#44,203 of 44,707

DCF data not available

Piotroski
3/9
Weak
Beneish
-2.81
Low Risk
Altman
0.78
Distress
DCF Value
-
N/A
ROIC
-27.8%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Tandem Diabetes Care, Inc. (TNDM) — VMCI valuation read

Composite valuation read on TNDM: VMCI 34/100 against a Healthcare sector median of 50. The 16-point below-median print is the headline number for Tandem Diabetes Care, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for TNDM: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on TNDM: TNDM trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of -1.1x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

TNDM fell 3.8% over the trailing 7 days, with a -17.8% read on a 30-day basis.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

CEO: John F. Sheridan2,650 employeesUSwww.tandemdiabetes.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in TNDM’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.